Latest News & Features
Americas
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), has filed a brief in support of Sandoz’s petition for certiorari in the pending Sandoz v Amgen case. 22 February 2017
Asia
Danish biotechnology company Novozymes has won a patent dispute against China-based enzyme makers Shandong Longda Bio-Products and Jiangsu Boli Bioproducts at the Supreme People’s Court of China. 21 February 2017
Americas
The US Department of Justice has asked for an injunction to stop a Louisiana-based drug and dietary supplement manufacturer from distributing misbranded and unapproved new drugs and dietary supplements. 21 February 2017
Americas
A scientist in Kansas has been convicted for conspiring to steal samples of genetically engineered rice seeds from a US biopharmaceutical research facility, Ventria Bioscience. 20 February 2017
Americas
Novartis has finalised its agreement with biopharmaceutical company Ionis Pharmaceuticals and its wholly-owned subsidiary Akcea Therapeutics to develop and commercialise therapies for cardiovascular disorders. 20 February 2017
Americas
Although the Patent Trial and Appeal Board gave a win to The Broad Institute of Harvard and MIT in the CRISPR patent conflict against the University of California, Berkeley and the University of Vienna, lawyers say the dispute may still not be resolved. 17 February 2017
Americas
Amgen has been accused of withholding confidential information about its proposed biosimilar of Genentech’s cancer drug Avastin. 17 February 2017
Americas
The US District Court for the District of New Jersey has found that a generic version of Helsinn Healthcare's drug Aloxi that was proposed by Dr Reddy's infringes three patents for the drug. 16 February 2017
Americas
The Broad Institute of Harvard and MIT’s patents concerning CRISPR technology do not interfere with patent claims filed by the University of California, Berkeley and the University of Vienna. 16 February 2017
Asia-Pacific
India-based Initiative for Medicines, Access & Knowledge has filed four patent challenges against patents covering hepatitis C drugs in a bid to ensure access to affordable treatment. 15 February 2017